Pages that link to "Q33382489"

The following pages link to Combination therapy with S-1 and pegylated interferon alpha for advanced hepatocellular carcinoma (Q33382489):

Displaying 12 items.

• Interferon lambda: a new sword in cancer immunotherapy (Q21296797) (← links)
• Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates (Q33832168) (← links)
• Current status of multimodal & combination therapy for hepatocellular carcinoma (Q36436294) (← links)
• Molecular targets of Chinese herbs: a clinical study of hepatoma based on network pharmacology (Q36865004) (← links)
• S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial (Q38789875) (← links)
• MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells (Q41576938) (← links)
• The 2008 Okuda lecture: Management of hepatocellular carcinoma: from surveillance to molecular targeted therapy (Q43108443) (← links)
• Safety and efficacy of adjuvant pegylated interferon therapy for metastatic tumor antigen 1-positive hepatocellular carcinoma. (Q44365724) (← links)
• Chinese medicine herbal treatment based on syndrome differentiation improves the overall survival of patients with unresectable hepatocellular carcinoma (Q44970853) (← links)
• Comparison of pegylated interferon α-2b plus psoralen PUVA versus standard interferon α-2a plus PUVA in patients with cutaneous T-cell lymphoma. (Q52767066) (← links)
• The cancer stem cell marker CD133 is a predictor of the effectiveness of S1+ pegylated interferon α-2b therapy against advanced hepatocellular carcinoma. (Q53308300) (← links)
• A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma (Q87691280) (← links)